Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown promising antitumor activity against a range of advanced cancers. However, evidence is lacking as to whether this combination therapy could benefit thymic epithelial tumors (TETs). We aimed to explore the efficacy and safety of this combination therapy in advanced TETs.

Methods

Ten patients with pathologically proven advanced TETs who received ICIs combined with an antiangiogenic agent from 2020 to 2022 at Zhejiang Cancer Hospital were included in the study. The Kaplan-Meier method was used to compare the treatment efficacy and survival outcomes.

Results

Of the cohort of ten patients who received immunotherapy combined with antiangiogenic targeting drugs, two patients achiev

SUBMITTER: Xiang J 

PROVIDER: S-EPMC10080305 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature